Care Coordination in Oncology, Quality Among Patients With Lung Cancer and Their Caregivers

NCT03694054 | Completed

• 1 other identifier: 2018-0172
• Study Type: interventional
• Target: 57
• Locations: 1 country
• Sites: 1

Brief Summary

The Oncology Care Coordination study is designed to evaluate use of a care coordination tool for lung cancer patients and their caregiver on quality of care and performance outcomes. Eligible patients need to be receiving treatment at Geisinger. Participation in the study involves completion of surveys, permission to review information from the patient's electronic health record, and for some enrollment in the care coordination tool called Harmonized Care. Geisinger oncology care providers who have patients enrolled the study will be invited for interviews.

Conditions

Lung Cancer

Keywords

Care Coordination; Oncology Care; Lung Cancer

Outcome Measures

Primary Outcomes (1)

• Patient Satisfaction

  To evaluate the difference in patient satisfaction associated with FCA exposure (Case v. Control) will be evaluated using chi-square test, t-tests and non-parametric univariate tests distribution dependent. Mean patient and caregiver scores will be calculated for each dyad and compared between groups. Sensitivity analyses may stratify by level of FCA use (low-moderate-high) per dyad and opportunity time for FCA exposure. Case to Control patient analyses will also be performed to detect role-level differences in perceptions of satisfaction associated with FCA exposure.To evaluate the association of the change in patient satisfaction associated with FCA use difference in response between pre- and post- surveys paired t-test or ANCOVA depending on data type and distribution. Within Case Dyads, patient means will be compared with caregiver means to detect difference in satisfaction perceptions based on role.

  8 weeks

Secondary Outcomes (6)

• Caregiver Satisfaction

  8 weeks

• Patient Quality of Life

  8 weeks

• Caregiver Quality of Life

  8 weeks

• Family Centered Care

  8 weeks

• Patient Experience

  8 weeks

Study Arms (3)

Care coordination patients, caregivers

EXPERIMENTAL

Patients and caregivers enroll in using care coordination tool during oncology care and treatment.

Other: Care coordination tool

Standard of care patients, caregivers

NO INTERVENTION

Patients and caregivers receive oncology care and treatment.

Oncology Care Providers

EXPERIMENTAL

Oncology care providers with patients enrolled in care coordination tool.

Other: Care coordination tool

Interventions

Care coordination tool OTHER

Participants will be asked to enroll in the care coordination tool, a health information technology solution that integrates cross-sector data to enhance communication and improve quality of care and performance outcomes. Patients will also be asked to provide consent to allow the study team to access additional health information via the electronic health record.

Care coordination patients, caregivers; Oncology Care Providers

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients:
• Patients who are 18 years of age or older and diagnosed with lung cancer who 1) are scheduled to start Oncology Care (chemo and/or radiation-therapies) OR 2) on active Oncology Care and recently started within 3 weeks (\<27 days for experimental arm; \<56 days control arm)
• Receive care at GMC, GWV, or GCMC
• English-speaking
• Established/intends to establish a MyGeisinger Account (cases only)
• Caregivers:
• Recognized/intends to be recognized as proxy for patient's MyGeisinger Account (cases only)
• English-speaking
• Providers:
• \- Any health care provider within Medical Oncology or Radiation Oncology at GMC, where care coordination tool is standard of care, who has a patient enrolled.

You may not qualify if:

• Patients:
• Patients who are not diagnosed with lung cancer.
• Patients who are diagnosed with lung cancer and are on active Oncology Care exceeding 3 weeks (\>27 days experimental arm; \>56 days control arm).
• Providers:
• Any healthcare provider not within the Medical Oncology or Radiation Oncology departments.
• Any healthcare provider within Medical Oncology or Radiation Oncology who does not have a patient enrolled (Case Dyad).

Sponsors & Collaborators

• Geisinger Clinic: lead
• Merck Sharp & Dohme LLC: collaborator

Study Sites (1)

Geisinger Health System

Danville, Pennsylvania, 17822, United States

Location

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Lisa Bailey-Davis, DEd, RD

  Geisinger Clinic

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 11, 2018
• First Posted: October 3, 2018
• Study Start: June 4, 2018
• Primary Completion: February 28, 2019
• Study Completion: March 31, 2019
• Last Updated: April 9, 2019

Record last verified: 2019-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)